Regarding the composite kidney outcome, investigators noted the incidence was greatest in the chronic kidney disease trials, with 3294 (4.5%) participants experiencing chronic kidney disease progression, including 3164 (96.1%) patients who were not receiving a GLP-1 receptor agonist at baseline
Li WX, Gou JF, Tian JH, Yan X, Yang L
If youve started to notice your skin looking thinner, looser, or more crepey after starting a GLP-1, youre not alone
Similar to the above described groups of neuropeptides, in humans, bombesin-like peptides (BLPs) have roles in many different physiological functions and pathological conditions from glucose homeostasis to malignancies [195, 196, 198]